The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Contribution to the development of precision medicine and clinical utility of nationwide lung cancer genomic screening in Japan (LC-SCRUM-Japan).
 
Kadoaki Ohashi
Honoraria - AstraZeneca Japan; Chugai Pharma
Research Funding - Boehringer Ingelheim; Novartis
 
Shingo Matsumoto
Honoraria - Novartis
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Kiyotaka Yoh
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Lilly Japan
Research Funding - AstraZeneca (Inst); Bayer (Inst); Lilly Japan (Inst); Novartis (Inst); Pfizer (Inst)
 
Yuichiro Ohe
Stock and Other Ownership Interests - Ono Pharmaceutical (I)
Honoraria - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Clovis Oncology; Daiichi Sankyo; Lilly Japan; MSD; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb Japan (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Kyorin (Inst); Lilly Japan (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
Expert Testimony - AstraZeneca
 
Tadasuke Shimokawaji
No Relationships to Disclose
 
Yuki Kataoka
Research Funding - Lilly
 
Masahiro Kodani
No Relationships to Disclose
 
Akimasa Sekine
No Relationships to Disclose
 
Sho Saeki
No Relationships to Disclose
 
Naoki Furuya
No Relationships to Disclose
 
Takashi Seto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Kissei Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; MSD; Nippon Boehringer Ingelheim; Nippon Kayaku; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Astellas Pharma (Inst); AstraZeneca Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst)
 
Takuma Yokoyama
No Relationships to Disclose
 
Masato Shingyoji
No Relationships to Disclose
 
Yoshihiro Hattori
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Novartis; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca
 
Young Hak Kim
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Kirin Pharmaceuticals; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Katsuya Tsuchihara
Honoraria - Takeda
 
Koichi Goto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Life Technologies; Lilly; Merck Serono; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; SRL Diagnostics; Taiho Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; Daiichi Sankyo
Research Funding - Abbvie; Amgen Astellas BioPharma; Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; OxOnc; Pfizer; Riken Genesis; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda